Analysts Expect Provention Bio, Inc. (NASDAQ:PRVB) to Post -$0.45 Earnings Per Share

Equities analysts forecast that Provention Bio, Inc. (NASDAQ:PRVBGet Rating) will report ($0.45) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Provention Bio’s earnings, with estimates ranging from ($0.50) to ($0.41). Provention Bio posted earnings per share of ($0.52) during the same quarter last year, which would indicate a positive year over year growth rate of 13.5%. The firm is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Provention Bio will report full year earnings of ($2.00) per share for the current financial year, with EPS estimates ranging from ($2.49) to ($1.59). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.83) per share, with EPS estimates ranging from ($1.74) to ($0.32). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Provention Bio.

Provention Bio (NASDAQ:PRVBGet Rating) last issued its quarterly earnings data on Thursday, February 24th. The company reported ($0.41) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.03. The business had revenue of $0.72 million for the quarter, compared to analyst estimates of $0.71 million. During the same period in the previous year, the business posted ($0.58) EPS.

Several analysts have issued reports on PRVB shares. Zacks Investment Research raised Provention Bio from a “sell” rating to a “hold” rating in a research note on Wednesday, March 2nd. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Provention Bio in a research note on Monday, January 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Provention Bio in a research note on Friday, April 1st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $16.18.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its position in shares of Provention Bio by 44.9% in the second quarter. Royal Bank of Canada now owns 6,534 shares of the company’s stock valued at $55,000 after buying an additional 2,026 shares in the last quarter. Denali Advisors LLC acquired a new position in Provention Bio during the fourth quarter valued at approximately $39,000. J.W. Cole Advisors Inc. acquired a new position in Provention Bio during the fourth quarter valued at approximately $73,000. BNP Paribas Arbitrage SA raised its position in Provention Bio by 92.1% during the third quarter. BNP Paribas Arbitrage SA now owns 13,092 shares of the company’s stock valued at $84,000 after purchasing an additional 6,278 shares in the last quarter. Finally, Ensign Peak Advisors Inc acquired a new position in Provention Bio during the fourth quarter valued at approximately $82,000. Institutional investors own 35.00% of the company’s stock.

Provention Bio stock traded up $0.16 during mid-day trading on Tuesday, hitting $5.96. 10,773 shares of the company’s stock were exchanged, compared to its average volume of 931,673. The firm has a market capitalization of $377.86 million, a P/E ratio of -3.27 and a beta of 2.60. Provention Bio has a fifty-two week low of $3.40 and a fifty-two week high of $11.49. The company’s 50 day simple moving average is $6.79 and its 200-day simple moving average is $6.22.

Provention Bio Company Profile (Get Rating)

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.

Further Reading

Get a free copy of the Zacks research report on Provention Bio (PRVB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Provention Bio (NASDAQ:PRVB)

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.